FinTechFunding

Atalanta Therapeutics: Raises $110M in Series A Funding

  • Atalanta Therapeutics, a Boston, MA-based biotechnology company pioneering new treatment options for neurodegenerative diseases, raised $110m in Series A funding
  • The financing was provided exclusively by F-Prime Capital
  • Additionally, Atalanta announced strategic collaborations with Biogen (Nasdaq: BIIB) and Genentech, a member of the Roche Group
  • As part of the strategic collaboration with Biogen, Atalanta will develop RNAi therapeutics for multiple targets
  • The company will be eligible to receive development and milestone payments on these programs as well as royalty payments on any resulting products
  • The strategic collaboration with Genentech involves the development of RNAi therapeutics for multiple CNS targets for neurodegenerative diseases
Previous article
Total Brain: Posts strong growth despite COVID-19 headaches
Next article
SpyGlass Ophthalmics: Closes $27.5M in Series B Financing
Steve Sam
Steve Sam
Steve Sam is a financial reporter, analyst, and commentator with a strong focus on banking technology, digital payments, and the future of financial services.

You May Also Like

FinTech

US FTC Reports Consumers Lost $15.9 Billion to Fraud in 2025

The FTC reveals alarming fraud losses impacting millions of Americans.Highlights: Consumers lost $15.9 billion to fraud in 2025,...
FinTech

EU, UK, and Switzerland Strengthen T1 Testing Plan for 2027 Transition

Three regions collaborate on testing ahead of joint financial move.Highlights: EU, UK, and Switzerland announce T1 testing plan.Collaboration...
FinTech

NextGen FinCrime Initiative Strengthens Cross-Sector Collaboration

New talks aim to enhance cooperation in tackling financial crime across industries.Highlights: NextGen FinCrime initiative aims to unite...
FinTech

Aviva Launches Insurance App on ChatGPT, Enhancing Customer Interactions

The new app aims to simplify insurance queries and support for users.Highlights: Aviva introduces an insurance app on...